Physician profile
Jenna M Bailey
NPI 1659891943
$6,989.79
in general payments reported to CMS, 2019-2025
20 companies · $3,291 in 2025
The $3,291 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $86.98 · 2021: $311 · 2022: $819 · 2023: $554 · 2024: $1,042 · 2025: $3,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,159 · Travel and Lodging: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,158.60 |
| Travel and Lodging | $728.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,077.30 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $749.32 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Alcon Vision LLC | $611.50 | 2019-2025 | Tryptyr, Precision7, Eysuvis |
| Abbvie INC. | $562.59 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $484.17 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $450.92 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $420.07 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $338.03 | 2019-2021 | |
| Shire North American Group INC | $258.44 | 2019 | |
| Allergan, INC. | $246.66 | 2021-2022 | |
| Dompe US, INC. | $195.50 | 2022-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $146.31 | 2019-2021 | |
| Oyster Point Pharma, INC. | $111.53 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $101.61 | 2021-2022 | |
| Harrow Eye, LLC | $69.82 | 2024-2025 | Vevye |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $68.94 | 2022-2025 | Myday Contact Lens, Paragon Crt |
| Novartis Pharmaceuticals Corporation | $55.83 | 2020-2023 | |
| Alimera Sciences, INC. | $19.02 | 2021 | |
| Genentech USA, INC. | $11.56 | 2019 | |
| Visioneering Technologies, INC. | $10.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.